Leo Cancer Care, a pioneer in radiotherapy treatment devices, announced the successful raise of approximately $40 million in a funding round led by Catalio Capital Management. The round also saw participation from new and existing investors.

This substantial investment will accelerate commercialization of Leo Cancer Care's next-generation upright radiotherapy system, designed to enhance patient outcomes and broaden access to advanced cancer treatment. As part of the funding round, Catalio's Dr. Nicholas von Guionneau, joins Leo Cancer Care's board as an Observer.